Methods for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist
The inventors initially participated to the identification of LPIN1 mutations as a cause for massive rhabdomyolysis episodes in children, triggered by febrile illness. The inventors have suggested that TLR9 antagonists would be suitable for the treatment of rhabdomyolysis (WO2017085115). The inventors thus treated 2 patients with lipin-1 disease by a TRL9 antagonist (hydroxychloroquine). They showed that the accumulation of mtDNA in plasma of the two patients before treatment decreases under treatment. When the treatment was stopped, the accumulation of mtDNA reappeared, then normalized when treatment was resumed. Accordingly, the present invention relates to a method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist comprising determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient (e.g. by PCR).
1. A method for determining whether a patient suffering from rhabdomyolysis achieves a response with a TLR9 antagonist and treating the patient, comprising:
(i) determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient;
(ii) comparing the amount determined at step (i) with a predetermined reference value; and
(iii) concluding that the patient achieves a response when the amount determined at step (i) is lower that the predetermined reference value, treating the patient with the TLR9 antagonist.
2. A method of claim for monitoring compliance of a patient being treated for rhabdomyolysis with a TLR9 antagonist, comprising:
(i) determining the amount of mitochondrial DNA (mtDNA) in a blood sample obtained from the patient;
(ii) comparing the amount determined at step (i) with a predetermined reference value obtained from the patient after treatment began; and
(iii) treating the patient with the TLR9 antagonist when an increase in the mtDNA compared to the predetermined reference value is detected, wherein the increase shows that the patient has failed to comply with the prescribed treatment.
3. The method of claim 1 , wherein the TFRL9 TLR9 antagonist is hydroxychloroquine.
4. The method of claim 1 , wherein the blood sample is a plasma sample.
5. The method of claim 1 , wherein the quantification of mtDNA is performed by immunofluorescence or by PCR.